BLS Pharmaceuticals Reports Strong Q1 FY27 Performance
Key points
- Record Q1 FY27 revenue of $26.7 million, up 23% from Q4 FY26
- Positive operating cash flow of $2.0 million for the quarter
- FY27 guidance reaffirmed: revenue of $105 million to $115 million
- Expansion of international manufacturing capabilities in Germany and the UK
- New commercial partnerships with Cayman Chemical and Trexapharm
Full summary
BLS Pharmaceuticals Ltd (ASX: BLS) reports a strong start to FY27, achieving a record quarterly revenue of $26.7 million, a 23% increase from Q4 FY26. The company generated positive operating cash flow of $2.0 million for the quarter, with customer cash receipts of $22.4 million. BLS has reaffirmed its FY27 guidance of $105 million to $115 million in revenue and an adjusted EBITDA margin of 23% to 26%. The company continues to grow its Australian manufacturing operations and international supply platform, including ongoing supply to Germany and progress on its Scotland GMP manufacturing facility. BLS also expanded its commercial opportunities through new relationships with Cayman Chemical and Trexapharm.
Guidance
FY27 revenue guidance of $105 million to $115 million and adjusted EBITDA margin of 23% to 26%
Outlook
BLS aims to increase Australian manufacturing capacity, grow volumes across customers, execute international supply agreements, onboard new pharmaceutical customers, progress the Scotland facility, and expand its international platform.
Summary generated by a large language model. Please interpret with care.